Financial PerformanceSpruce Biosciences ended 3Q24 with $60.1M in cash and cash equivalents, which is expected to be sufficient to fund operations at least into 2026.

Market OpportunityThere is an opportunity in CAH that affects approximately 20,000-30,000 patients in the U.S., supporting multiple drugs.

PartnershipsSpruce Biosciences entered a low-risk partnership with HMNC Brain Health to run a Phase 2 proof-of-concept trial of tildacerfont in major depressive disorder.

Bears Say

Clinical TrialsThe CAHmelia-204 and CAHptain-205 clinical trials will be discontinued; the company plans to wind down its investment in tildacerfont for the treatment of CAH.

Financial PerformanceShares of Spruce Biosciences were trading at approximately 37% of end-quarter cash before the news, and were down around 22% in the aftermarket.

Regulatory ChallengesTildacerfont faces an uncertain future at best, particularly in the wake of the recent U.S. regulatory approval of crinecerfont.

---

Financials

Annual

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

19.78% Insiders

2.56% Mutual Funds

24.66% Other Institutional Investors

50.98% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Detailed Risk Analysis >

Website Traffic

Sorry, No Data Available

There is no website visitor data available for this stock.

---

SPRB FAQ

What was Spruce Biosciences’s price range in the past 12 months?

Spruce Biosciences lowest stock price was $0.34 and its highest was $5.95 in the past 12 months.

What is Spruce Biosciences’s market cap?

Spruce Biosciences’s market cap is $15.82M.

When is Spruce Biosciences’s upcoming earnings report date?

Spruce Biosciences’s upcoming earnings report date is Mar 12, 2025 which is in 52 days.

How were Spruce Biosciences’s earnings last quarter?

Spruce Biosciences released its earnings results on Nov 11, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.238 by $0.028.

Is Spruce Biosciences overvalued?

According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Spruce Biosciences pay dividends?

Spruce Biosciences does not currently pay dividends.

What is Spruce Biosciences’s EPS estimate?

Spruce Biosciences’s EPS estimate is -0.21.

How many shares outstanding does Spruce Biosciences have?

Spruce Biosciences has 41,302,600 shares outstanding.

What happened to Spruce Biosciences’s price movement after its last earnings report?

Spruce Biosciences reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.238. Following the earnings report the stock price went down -1.852%.

Which hedge fund is a major shareholder of Spruce Biosciences?

Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at 0.

---

Company Description

Spruce Biosciences

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

---